Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
BOSTON & OSAKA, Japan--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential being studied for the treatment of immunoglobulin A nephropathy (IgAN), primary membranous nephropathy (pMN) and other B cell-mediated diseases.
Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory and commercial milestone payments and tiered royalties. Ono will utilize its extensive development expertise to help advance Vertex's clinical trials for povetacicept and will be responsible for obtaining marketing authorizations in Japan and South Korea. Following approval, Ono will be solely responsible for commercializing povetacicept in these regions. The agreement includes povetacicept for both IgAN and pMN, with the potential to add other indications.
'Ono is a proven leader in Japan and South Korea, bringing established local relationships, infrastructure and nephrology expertise that make them a perfect partner for Vertex as we look to deliver povetacicept to the thousands of potential patients in these countries,' said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. 'We are very pleased to partner with Ono and look forward to close collaboration as we continue to advance this potentially best-in-class treatment for IgAN, pMN and other serious B cell-mediated diseases.'
'Vertex has a strong track record of developing innovative therapies for serious diseases. Through this strategic partnership, we can strengthen our late-stage pipeline in the immunology field, which is a key focus area for Ono,' said Toichi Takino, Representative Director, President and Chief Operating Officer of Ono. 'We look forward to collaborating with Vertex to provide this new therapeutic option for patients with IgAN and other autoimmune diseases in Japan and South Korea, and to maximize the value of this treatment.'
About Povetacicept
Povetacicept is a recombinant fusion protein therapeutic and a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, which play key roles in pathogenesis of multiple autoimmune diseases via their roles in the activation, differentiation and/or survival of B cells, T cells and innate immune cells. Based upon an engineered TACI (transmembrane activator and calcium modulator ligand interactor) domain, povetacicept has higher binding affinity and greater potency in preclinical studies versus other inhibitors of BAFF and/or APRIL alone and has demonstrated potential best-in-class efficacy in a clinical trial in patients with IgA nephropathy and primary membranous nephropathy. Povetacicept is also in development for multiple serious B cell-mediated diseases including other autoimmune kidney diseases and autoimmune cytopenias.
About IgA Nephropathy (IgAN)
IgAN is a serious, progressive, life-threatening, B cell-mediated chronic kidney disease that is the most common cause of primary (idiopathic) glomerulonephritis, affecting approximately 300,000 people in the United States and Europe. It is estimated that there are approximately 33,000 diagnosed patients in Japan. IgAN results from deposition of circulating immune complexes consisting of immunoglobulins and galactose-deficient immunoglobulin A (Gd-IgA1) in the renal glomerular mesangium, triggering kidney injury and fibrosis. Up to 72% of adult IgAN patients progress to end-stage renal disease within 20 years. There are no approved therapies that specifically target the underlying cause of IgAN.
About Primary Membranous Nephropathy (pMN)
Primary membranous nephropathy is a serious, progressive, life-threatening B cell-mediated chronic kidney disease affecting people worldwide, with approximately 150,000 people diagnosed in the U.S. and Europe. It is estimated that there are approximately 6,000 diagnosed patients with pMN in Japan. pMN is a rare glomerular disease that occurs when the body generates an abnormal immune response, including autoantibodies, against proteins that are part of the kidney. Autoantibodies trigger damage and inflammation, especially within the glomeruli (the parts of the kidney that filter blood), impairing the kidneys' ability to properly filter waste and fluid, eventually causing progressive loss of kidney function. There are no approved therapies that specifically target the underlying cause of pMN.
About RAINIER
RAINIER is a global Phase 3 pivotal trial of povetacicept 80 mg vs. placebo on top of standard of care in approximately 480 people with IgAN. The study is designed to have a pre-planned interim analysis evaluating urine protein to creatinine ratio (UPCR) for the povetacicept arm versus placebo after a certain number of patients reach 36 weeks of treatment. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval in the U.S. Final analysis will occur at two years of treatment, with a primary endpoint of total eGFR slope through Week 104.
The Phase 3 clinical trial is underway in multiple regions, including the U.S., EU and Asia. Specifically, Japanese and South Korean regulatory authorities have approved the Clinical Trial Application (CTA) for RAINIER, where the Phase 3 trial is underway.
About RUBY-3
RUBY-3 is an ongoing, multiple ascending dose, multi-cohort, open label, Phase 1/2 basket study of povetacicept in autoimmune glomerulonephritis, including IgAN, primary membranous nephropathy, lupus nephritis and ANCA-associated vasculitis with glomerulonephritis where povetacicept is being administered subcutaneously for up to 104 weeks.
About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.
Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.
About Ono Pharmaceutical Co., Ltd
Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of 'Dedicated to the Fight against Disease and Pain,' Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at https://www.ono-pharma.com/en.
Vertex Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements by Reshma Kewalramani M.D., and Toichi Takino, in this press release, and statements about the terms of and expectations for Vertex's collaboration with Ono, statements about potential benefits and results that may be achieved through the collaboration, statements regarding the future activities of the parties pursuant to the collaboration, including Ono's help to advance clinical trials and Ono's responsibility to obtain marketing authorizations in Japan and South Korea and to commercialize povetacicept in the regions, statements regarding upfront and milestone payments, and potential royalties on future products, and statements about Vertex's plans and expectations for the RAINIER and RUBY-3 clinical trials and potential plans to seek accelerated approval in the U.S. based on interim analysis from the RAINIER trial. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the anticipated benefits and potential of the collaboration between Vertex and Ono may not be achieved on the anticipated timeline, or at all, that data may not support further development of the therapies subject to the collaboration due to safety, efficacy, or other reasons, and other risks listed under the heading 'Risk Factors' in Vertex's annual report filed with the Securities and Exchange Commission (SEC) and available through Vertex's website at www.vrtx.com and on the SEC's website at www.sec.gov. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
(VRTX-GEN)
Ono Forward-Looking Statements
In this press release, statements made with respect to current plans, estimates, strategies and beliefs, and other statements that are not historical facts are forward-looking statements about the future performance of the company. These statements are based on current assumptions and beliefs in light of the information currently available and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in the business environment in the pharmaceutical market and amendments to relevant laws and regulations, (ii) disruptions to product supply due to stagnation or delays in production caused by natural disasters, fires, etc., (iii) the possibility that sales activities for new and existing products may not achieve the expected results, (iv) the emergence of new side effects in post-marketing drugs, and (v) infringements of intellectual property rights by third parties. Information about pharmaceutical products included in this press release is not intended to constitute an advertisement or medical advice.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Should You Buy Roku Stock After Its Partnership With Amazon?
Roku's recent partnership with Amazon makes the streaming specialist more attractive. Although it still faces some headwinds, Roku's long-term prospects remain bright. The stock doesn't look too expensive at current levels, either. 10 stocks we like better than Roku › On June 16, Roku (NASDAQ: ROKU) announced a partnership with Amazon (NASDAQ: AMZN) that will allow advertisers access to the streaming specialist's ecosystem through Amazon's advertising platform. This agreement represents a significant move forward for Roku. Although the stock has encountered some headwinds over the past year, this new development once again highlights why Roku stock is worth investing in for those focused on the long game. Let's dig deeper into this partnership between Roku and Amazon -- as well as the rest of the former's business -- to understand why. Amazon is a notable player in the connected TV (CTV) market. However, Roku continues to reign supreme -- it holds a leading market share in the U.S. Amazon's size advantage has not allowed it to take over the top spot, and it's now partnering with its longtime rival. Amazon and Roku will combine their respective audiences, comprising 80 million households and more than 80% of CTV accounts in the U.S., and grant advertisers exclusive access to this large ecosystem through Amazon's demand-side ad platform. This is a win for Roku too. Here's why. One significant long-term opportunity for the company is the continued switch from cable to streaming for viewers and advertisers. However, a highly fragmented CTV landscape presented advertisers with several challenges, including difficulties in reaching targeted audiences across various platforms and effectively managing ad frequency. Roku noted in a recent press release: Early tests of this integration have shown significant results. Advertisers using this new solution reached 40% more unique viewers with the same budget and reduced how often the same person saw an ad by nearly 30%, enabling advertisers to benefit from three times more value from their ad spend. In other words, advertisers should get greater returns from the same amount of spending. The deal helps address some pain points they had and helps sell even more companies on the benefits of pouring ad dollars into the kind of platform that Roku offers. It's worth highlighting again that this deal is valuable to every party involved, largely because of Roku's leading CTV ecosystem. It also points to the strength of its network effect. Since the value of Roku's platform only increases as its audience numbers grow, partnerships of this kind could become more common. Roku has encountered some issues in recent years. Its average revenue per user (ARPU) has stalled, while it remains unprofitable. Though the company no longer reports the ARPU metric, management previously attributed poor ARPU growth to the company's expansion efforts in markets outside the U.S., where it is focusing on scale first, rather than monetization. That's the same blueprint it followed in its more mature markets when it sometimes sold its namesake devices at a loss to onboard enough households within its ecosystem. Investors have seen the results of this strategy in the U.S., where Roku already holds a leading market share. This should give investors confidence that it can achieve similar results in other regions. What about the persistent red ink on the bottom line? Investors vastly prefer profitable companies, especially in this uncertain economic and geopolitical environment. But Roku is making strides in this department too. In the company's first quarter, revenue came in at $1.03 billion, up 16% year over year. The company's net loss per share was $0.19, an improvement from the $0.35 per share loss it reported in the prior-year quarter. Roku might not be consistently profitable, but the company is growing its top line at a good clip and making progress on the bottom line. And overall, the company is still in a great position to cash in on the massive long-term shift from cable to streaming. And here's one more thing that makes the stock attractive. Roku's forward price-to-sales ratio is 2.6 as of this writing. In a stock market at all-time highs and valuations reaching unsustainable levels, Roku's modest valuation is especially rare for a growth stock in a leading industry position. For this and all the other reasons, it's worth purchasing the company's shares. Before you buy stock in Roku, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Roku wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Prosper Junior Bakiny has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Roku. The Motley Fool has a disclosure policy. Should You Buy Roku Stock After Its Partnership With Amazon? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
3 hours ago
- CNBC
The record-breaking week in the stock market that could have gone very badly
It was another exciting week on Wall Street as the S & P 500 and Nasdaq each closed Friday at new record highs. Incredible as that was, this week could have easily gone another way. Last Saturday, the world learned that the U.S. had entered the Israel-Iran conflict, dropping several massive bunker busters on Fordo, Iran's underground nuclear facility buried under a mountain, and bombing two other sites, Isfahan and Natanz. While fear of further escalation and a prolonged war involving the U.S. was palpable last weekend, the market on Monday shrugged, betting on the notion that the conflict would not result in systemic risk or slow the U.S. economy and hamper corporate earnings much, if at all. As risky as any military action is given the potential to spiral out of control, they tend not to impact the market for long, unless signs appear that it will start impacting growth and inflation. That has not yet happened. We did see energy prices surge in the week before last Saturday's bombings, but they quickly came back down. West Texas Intermediate crude plunged on Monday and Tuesday. While rising modestly in each subsequent session, WTI plunged more than 11% for the week, breaking a three-week winning streak. The stock market took its cues from oil trading, which allowed for the S & P 500 and Nasdaq records and weekly gains of nearly 3.5% and more than 4%, respectively. Monday is the last day of June and Wall Street's second quarter. For the week ... S & P 500 week to date (WTD) up 3.44%; first positive week in three Month to date (MTD) up 4.42%; on pace for its second positive month in a row Quarter to date (QTD) up 10%; on pace for its best quarter since first quarter 2024 Nasdaq WTD up 4.25% MTD up 6%; on pace for its third positive month in a row QTD up 17.2%; best quarter since second quarter 2020 Energy represents a major input cost, often one of the largest, for just about every business in the world, so a sustained increase in energy prices would crunch profit margins or force price hikes in order to preserve them. At the same time, it represents a large unavoidable cost for consumers, whether they're trying to air condition their homes in the summer, heat their homes in the winter, or fill up their cars. Given these high priority needs, elevated energy costs end up cutting into discretionary budgets – meaning activities such as eating out or shopping would get cut back. The quick pairing back of those energy price increases this past week, however, means that analysts don't need to downwardly revise estimates for growth, inflation, or consumer spending – at least not yet. The full impact of President Donald Trump 's tariffs is still unclear, though they will almost certainly lead to higher prices for consumers. While the de-escalation of tensions in the Mideast, and subsequent pullback in energy prices, were certainly the most important factors supporting this week's market action, interest rate expectations were also in focus. Though several voting members of the Federal Reserve's policymaking committee, including Fed Chairman Jerome Powell , threw cold water on comments from Fed Governors Christopher Waller and Michelle Bowman that they were on board with a July rate cut, investors have nonetheless started to price in a higher likelihood that we see three Fed rate cuts by year-end, up from the odds of just two cuts only a week ago. That's according to the CME FedWatch Tool . Another important update that could influence interest rate decisions came Friday, with the release of the May personal income and spending report. Within that report, we find the personal consumption expenditures (PCE) price index, the Fed's preferred measure of inflation. While headline PCE was in line with expectations, up 0.1% month over month and up 2.3% annually, the core rate was a bit hotter than expected, rising 0.2% month over month and 2.7% versus the year-ago period, both one-tenth of a percentage point above expectations. The warmer core reading, which excludes food and energy, is something to watch and cuts against the case for a July rate cut. Digging into the portfolio, we hosted our June Monthly Meeting this week, providing a rundown of all 30 holdings. Jim Cramer highlighted six rallying stocks that members may want to consider booking profits in, and five others that look like buys. We also answered key member questions and touched on all 10 names in our Bullpen, including Cisco Systems, which was added on Monday . The Bullpen is our watch list of stocks that could, under the right circumstances, join the Charitable Trust. During the June meeting, Jim was itching to buy Cisco and Boeing but decided to wait. Sticking with portfolio updates, Nvidia hit new all-time highs this past week as sentiment around artificial intelligence and data center demand continued to improve. Analysts at Loop Capital slapped a $250-per-share price target on the stock, highlighting the hyperscaler purchase intentions over the next few years, the compute intensity of reasoning models, and increased inference demand resulting from AI agent adoption. Already regaining the title of the most valuable U.S. public company at more than $3.8 trillion, Nvidia at $250 represents roughly 60% upside to Friday $157 close and a market cap of more than $6 trillion. Needless to say, Nvidia was our top performer for the week up more than 9.5%. Data center plays — Eaton, GE Vernova, and Broadcom are also expected to benefit from the AI strong demand. On Tuesday, analysts at Morgan Stanley raised their price target on GE Vernova, while analysts at HSBC upgraded Broadcom to a buy from a hold rating. Broadcom, Eaton , and GE Vernova were our next best stocks for the week. Goldman Sachs rounded out the week's top five as financial stocks got some incrementally positive news this week when the Fed, on Wednesday, proposed lowering capital requirements for large U.S banks that were implemented in the years following the 2008 financial crisis. The move would allow banks, including Club holdings Goldman and Wells Fargo , to lend more freely while making it easier for them to buy more U.S. government bonds. Amazon continues to be in the news as investors work to better understand the opportunity the company has in new areas like online grocery shopping, thanks to its massive logistics network and the implications of advancing it through generative AI, robotics and autonomous vehicles. In health care, shares of Eli Lilly advanced this week despite data released Monday on the company's experimental weight-loss drug, bimagrumab, which is designed to help patients preserve muscle mass. It failed to wow investors. Abbott Laboratories , meanwhile, got some positive news Tuesday when Health & Human Services Secretary Robert F. Kennedy Jr. said that his department will encourage the use of wearable health devices. "My vision is every American is wearing a wearable within four years," RFK Jr. said at a House Energy and Commerce Committee meeting . The news may also bode well for devices like the Apple Watch, especially as more health-related sensors are built in. Speaking of Apple , we still believe it is an incredible company with the "greatest product in the world," as Jim put it , referring to the iPhone. However, we think the company would benefit from modifying its capital allocation plans , focusing less on the buyback and more on AI development, be it via internal R & D, paying up for top talent, or acquiring groundbreaking startups. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Yahoo
3 hours ago
- Yahoo
Hesai Group (HSAI) Soars 19.26% as New Lidar Secures Safety Certification
Hesai Group (NASDAQ:HSAI) is one of the . Hesai Group soared by 19.26 percent on Thursday to end at $23.10 apiece after achieving a new milestone for its ATX Lidar and safety certification portfolio. In a statement, Hesai Group (NASDAQ:HSAI) said that its ATX, a compact, high-resolution, long-range lidar, officially obtained ISO 26262 ASIL B functional safety certification from SGS-TÜV, the world's leading testing, inspection, and certification institution. ATX marked its fourth ISO 26262 accreditation after after Pandar128, QT128, and AT128. With the new certification, Hesai Group (NASDAQ:HSAI) said it now holds the highest number of ISO 26262 certified products in the world. ISO 26262 is a key standard for the functional safety of electrical and electronic (E/E) systems in vehicles. It calls for carefully planned safety measures at every step of the development process—from safety management and concept design, to system, hardware, and software development. Logistics robots filling packages in a warehouse, preparing for delivery. As vehicles become more dependent on E/E systems, ISO plays an important role in ensuring vehicle components adhere to the most stringent safety standards to reduce costly recalls and prevent passenger injuries. While we acknowledge the potential of HSAI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
